STOCK TITAN
  1. Home
  2. News
  3. DYAI

Dyadic International Inc., DE - DYAI STOCK NEWS

Welcome to our dedicated news page for Dyadic International Inc., DE (Ticker: DYAI), a resource for investors and traders seeking the latest updates and insights on Dyadic International Inc., DE.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Dyadic International Inc., DE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Dyadic International Inc., DE's position in the market.

News
Dyadic Reports 2023 Full Year Results and Recent Company Progress
Rhea-AI Summary
Dyadic International, Inc. announced the closing of a $6.0 million convertible note in a private placement. They reported positive topline data from a Phase 1 trial for their COVID-19 vaccine candidate, DYAI-100. Dyadic also entered into multiple fully funded vaccine and antibody projects, executed a term sheet for microbial protein production, and announced strategic partnerships for rabies prophylactics and bio-threat solutions. They expanded collaborations with various organizations and published preclinical studies. The company highlighted financial results, board changes, and upcoming conference calls.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Dyadic Announces Change in Board and Management Leadership Roles
Rhea-AI Summary
Dyadic International, Inc. announces changes in board leadership with Michael Tarnok stepping down as Chairman and Patrick Lucy appointed as his successor. Dr. Barry Buckland retires, reducing the Board size. Joseph Hazelton appointed as Chief Operating Officer. Patrick Lucy brings extensive biotechnology experience and aims to maximize shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.45%
Tags
none
-
News
Dyadic to Attend Industry Events in April
Rhea-AI Summary
Dyadic International, Inc. announces its participation in upcoming industry events to showcase its innovative microbial platforms for protein bioproduction and biopharmaceutical products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.16%
Tags
conferences
News
Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
Rhea-AI Summary
Dyadic International, Inc. announces successful trial of C1-produced monoclonal antibody against SARS-CoV-2 in hamster and nonhuman primate models. The study shows promising results for preventive and therapeutic medicines, highlighting the advantages of Dyadic's C1-expression system in developing human monoclonal antibodies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.66%
Tags
none
-
News
Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California
Rhea-AI Summary
Dyadic International, Inc. announces attendance at Future Food-Tech event to showcase its Dapibus™ Microbial Expression System and partnership with Biftek, Inc. for animal-free growth media supplement. The company aims to revolutionize protein expression and production in various industries while reducing costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.4%
Tags
conferences
-
News
Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
Rhea-AI Summary
Dyadic International, Inc. announces financial results for 2023 and a corporate update conference call on March 28, 2024. The company focuses on microbial protein production platforms for biopharmaceutical products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
conferences earnings
News
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
Rhea-AI Summary
Dyadic International, Inc. announced a private placement of $6.0 million of 8.0% Senior Secured Convertible Promissory Notes due March 8, 2027, with immediate family members and family trusts related to the CEO. The Convertible Notes can be converted into common stock at $1.79 per share, aiming to drive revenue growth and global adoption of Dyadic's technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.8%
Tags
none
-
News
Dyadic to Attend Industry Events in March
Rhea-AI Summary
Dyadic International, Inc. announces its participation in key industry events in March 2024 to showcase its innovative microbial platforms for protein bioproduction and biopharmaceutical products. The events include BIO-Europe Spring in Barcelona, Future Food-tech in San Francisco, and Vaccine Innovation Forum in Shanghai, where Dyadic will present its new vaccine development using the C1 platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
conferences
-
News
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
Rhea-AI Summary
Dyadic International, Inc. announces a strategic partnership with Rabian BV to develop affordable rabies vaccines using Dyadic's C1 protein production platform. The collaboration aims to address the global burden of rabies, leveraging expertise in virology and innovative technology to tackle the challenges posed by the disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
partnership
News
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
Rhea-AI Summary
Dyadic International, Inc. (DYAI) partners with Israel Institute for Biological Research (IIBR) to target emerging diseases. The collaboration aims to develop innovative solutions using Dyadic's microbial platforms and IIBR's antibodies discovery capabilities for effective treatments and vaccines. The partnership focuses on global health challenges with potential future commercialization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.85%
Tags
acquisition
Stock DYAI logo
Dyadic International Inc., DE

Nasdaq:DYAI

DYAI Rankings

#4755 Ranked by Market Cap
#3971 Ranked by Stock Gains
N/A Ranked by Dividends

DYAI Stock Data

50.99M
18.70M
30.18%
15.57%
0.63%
All Other Basic Organic Chemical Manufacturing
Manufacturing
Link
United States
Jupiter

About DYAI

dyadic international, inc. (otcqx: dyai) - we are a global biotechnology company focused on further improving and leveraging the patented and proprietary c1 expression system to help bring biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers to improve access and cost to patients and the healthcare system - but most importantly to save lives.